Suchergebnisse - "Russell, Nigel"

PubPharm (364)

1

Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations

enthalten in: American journal of hematology | 2024

von Khan, A. | James, D. | Andresen, V. | +14

2

A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia : Results from the LI-1 trial

enthalten in: British journal of haematology | 2024

von Copland, M. | Ariti, C. | Thomas, I. | +10

3

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Russell, N. | Wilhelm-Benartzi, C. | Othman, J. | +117

4

Post induction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

enthalten in: Blood | 2024

von Othman, J. | Potter, N. | Ivey, A. | +17

5

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy

enthalten in: Blood | 2024

von Othman, J. | Tiong, I. | O'Nions, J. | +33

CommentIn: Blood. 2024 Jan 25;143(4):296-298. - PMID 38270942

6

Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML

enthalten in: Blood advances | 2024

von Jimenez-Chillon, C. | Othman, J. | Taussig, D. | +29

7

Optimal Post-Remission Consolidation Therapy in Patients with AML

enthalten in: Acta haematologica | 2024

von Jimenez-Chillon, C. | Dillon, R. | Russell, N.

8

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML : the UK NCRI AML18 trial

enthalten in: Blood | 2023

von Freeman, S. | Thomas, A. | Thomas, I. | +19

CommentIn: Blood. 2023 Nov 16;142(20):1673-1674. - PMID 37971761

9

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

enthalten in: Leukemia | 2023

von Othman, J. | Potter, N. | Mokretar, K. | +35

10

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS : the UK NCRI AML19 trial

enthalten in: Blood advances | 2023

von Othman, J. | Wilhelm-Benartzi, C. | Dillon, R. | +19

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[37]